Table 4

Studies reporting switch between anti-IL-1 treatments

StudyTreatment switchPatientNReasons for switching
Eroglu et al 201636 Anakinra to canakinumabCAPS3Local reactions at injection site (n=2); pain at injection site and non-compliance (n=1)
Parker et al 201645 Anakinra to canakinumabCAPS13Due to canakinumab availability
Houx et al 201538 Anakinra to canakinumabCAPS48Personal convenience
Anton et al 201534 Anakinra to canakinumabCAPS5More convenient administration (n=4); severe local reactions to anakinra (n=1)
Rossi-Semerano et al 201586 Anakinra to canakinumabCAPS3Inefficacy or loss of efficacy, AE, persistent remission, or patient request
Russo et al 201465 Anakinra to canakinumabCAPS5Inadequate control of disease activity (n=5); poor compliance with daily injection of anakinra (n=3); patien/parent preference (n=2)
Kuemmerle-Deschner et al 201359 Anakinra to canakinumabCAPS (MWS)10Treatment failure (n=3); patient/parent preference (n=7)
Wittkowski et al 201167 Anakinra to canakinumabCAPS10Lack of efficacy or parent preference (n=10)
Kuemmerle-Deschner et al 201157 Anakinra to canakinumabCAPS (MWS)6Inconvenience of daily injection and secondary treatment failure (n=6)
Kone-Paut et al 201739 Canakinumab to anakinraCAPS (CINCA/NOMID)1Reason not reported
Parker et al 201645 Canakinumab to anakinraCAPS5One patient was initially treated with canakinumab but changed to anakinra during pregnancy, and then restarted canakinumab following a successful pregnancy. Incomplete response (n=3); for better response (n=1)
Lane et al 201541 Canakinumab to anakinraCAPS (CINCA/NOMID and MWS)2AEs
Ter Haar et al 201693 Anakinra to canakinumabHIDS/MKD2Inadequate efficacy (n=2)
Rossi-Semerano et al 201586 Anakinra to canakinumabHIDS/MKD4Inefficacy or loss of efficacy, AE or patient request
Galeotti et al 201278 Anakinra to canakinumabHIDS/MKD4More convenient dosing schedule and to avoid injection site reaction (n=4)
  • N is the total number of patients who were switched from one treatment to another. n is the number of patients who reported the particular reason for switching.

  • AEs, adverse events; CAPS, cryopyrin-associated periodic syndromes; CINCA, chronic infantile neurological cutaneous and articular syndrome; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; MWS, Muckle–Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease.